| 產品名稱 |
P25.48 |
| 商品貨號 |
B165451 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Cancer |
| Applications |
The antibody reacts with malignant prostatic epithelium but not with benign prostate epithelium. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human prostate cancer |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human prostate cancer |
| Comments |
Animals were immunized with fresh prostate cancer (tumor P251). Spleen cells were fused with NS-1 myeloma cells. The antibody reacts with malignant prostatic epithelium but not with benign prostate epithelium. |
| Complete Growth Medium |
Culture medium: RPMI 1640 with non-essential amino acids, 2 mM L-glutamine,
0.2 mM hypoxanthine and 0.032 mM thymidine, 90%; fetal bovine serum, 10%. |
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype |
IgG3 |
| Name of Depositor |
Sloan-Kettering Institute for Cancer Research |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Bazinet M, et al. Monoclonal antibodies selective for prostate cancer. US Patent 4,970,299 dated Nov 13 1990
|
